Multiepitope Vaccines against Neglected, Emerging, and Re-emerging Global Diseases

Dear Colleagues,

Neglected Global Diseases are infectious diseases and other conditions that cause physical and cognitive impairments, including maternal, infant and child health conditions; neglected tropical diseases; as well as malaria, tuberculosis, and HIV/AIDS. As climate change pushes the natural selection of pathogens and their vectors and natural reservoirs, the risk of these neglected diseases emerging within a larger global population poses an even greater threat. Vaccination is still viewed as the most effective method of preventing these infectious diseases by inducing protective immunity. Reverse vaccinology and immunoinformatics approaches have improved vaccine development and enabled the rapid identification of putative vaccine antigens by screening genomes and/or proteomes; in turn, they have led to the generation of multiepitope vaccines with superior effectiveness. This vaccine platform comprises short immunogenic determinants rather than an entire protein to elicit cellular and humoral immune responses, inducing long-term protection. Such a platform is extremely advantageous due to its safety, rapid production (unlike the traditional vaccines), and low cost; moreover, it has already been utilized in numerous vaccine design studies, generating promising results for several target pathogens, such as dengue virus, Trypanosoma cruzi, Ebola virus, Schistosoma, and SARS cov-2 virus, among several others. 

This Special Issue invites articles and reviews involving multiepitope vaccine design against neglected, emerging, and re-emerging global diseases, as well as methodologies, novel evaluation, and prediction tools for vaccine design improvement. This issue also welcomes works involving the recombinant production and in vitro and/or in vivo validation of these chimeric vaccines.

Dr. Cerrone Cabanos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunoinformatics
• structure-based
• reverse vaccinology
• multiepitope
• mRNA
• vaccines
• glycosylation
• disulfide-engineering
• recombinant production
• modeling
• pathogens
• neglected global diseases
• molecular dynamics
• immune simulation